Log in

Prevail Therapeutics Price Target & Analyst Ratings (NASDAQ:PRVL)

$10.47
-0.23 (-2.15 %)
(As of 10/22/2019 06:00 AM ET)
Today's Range
$10.11
Now: $10.47
$10.99
50-Day Range
$8.96
MA: $11.20
$14.62
52-Week Range
$7.41
Now: $10.47
$16.90
Volume74,367 shs
Average Volume112,516 shs
Market Capitalization$356.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Analyst Ratings

Prevail Therapeutics (NASDAQ:PRVL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Prevail Therapeutics in the last 12 months. Their average twelve-month price target is $18.33, suggesting that the stock has a possible upside of 75.10%. The high price target for PRVL is $20.00 and the low price target for PRVL is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.33$18.33$20.00N/A
Price Target Upside: 75.10% upside94.62% upside72.12% upsideN/A

Prevail Therapeutics (NASDAQ:PRVL) Consensus Price Target History

Prevail Therapeutics (NASDAQ:PRVL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/11/2019WedbushReiterated RatingOutperformHigh
7/15/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00Low
7/15/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$15.00High
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
(Data available from 10/22/2017 forward)
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is Blockchain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel